RxDoctor Payments Data

Trevor Cable

Physician Assistant · Norfolk, VANPI 1376146241

Payments from drug & device makers

$1,832in general payments, 2019–2025

Across 80 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$270
  • Johnson & Johnson$268
  • Sumitomo Pharma America, Inc.$265
  • Olympus America Inc.$184
  • Ardelyx, Inc.$148
  • Ipsen Biopharmaceuticals, Inc$91
  • plus $606 from 15 others

What the payments were for

  • Food & beverage$1,832100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,832 in reported general payments places this provider in the 80th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$86,740
Medicare patients
831
Services billed
1,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron106$82,818
MyrbetriqMirabegron37$40,308
Tamsulosin Hcl677$10,942
Finasteride350$5,400
Testosterone38$4,804
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl15$3,933
Dutasteride54$2,967
Alfuzosin Hcl ErAlfuzosin Hcl86$1,976
Testosterone Cypionate36$1,081
Tadalafil17$467
Cephalexin40$346
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$123
Ciprofloxacin Hcl16$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$265$82,818106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →